Literature DB >> 34747265

A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing.

Aasthaa Bansal1, Patrick J Heagerty2, Lurdes Y T Inoue2, David L Veenstra1, Charles J Wolock2, Anirban Basu1.   

Abstract

BACKGROUND: Patient surveillance using repeated biomarker measurements presents an opportunity to detect and treat disease progression early. Frequent surveillance testing using biomarkers is recommended and routinely conducted in several diseases, including cancer and diabetes. However, frequent testing involves tradeoffs. Although surveillance tests provide information about current disease status, the complications and costs of frequent tests may not be justified for patients who are at low risk of progression. Predictions based on patients' earlier biomarker values may be used to inform decision making; however, predictions are uncertain, leading to decision uncertainty.
METHODS: We propose the Personalized Risk-Adaptive Surveillance (PRAISE) framework, a novel method for embedding predictions into a value-of-information (VOI) framework to account for the cost of uncertainty over time and determine the time point at which collection of biomarker data would be most valuable. The proposed sequential decision-making framework is innovative in that it leverages the patient's longitudinal history, considers individual benefits and harms, and allows for dynamic tailoring of surveillance intervals by considering the uncertainty in current information and estimating the probability that new information may change treatment decisions, as well as the impact of this change on patient outcomes.
RESULTS: When applied to data from cystic fibrosis patients, PRAISE lowers costs by allowing some patients to skip a visit, compared to an "always test" strategy. It does so without compromising expected survival, by recommending less frequent testing among those who are unlikely to be treated at the skipped time point.
CONCLUSIONS: A VOI-based approach to patient monitoring is feasible and could be applied to several diseases to develop more cost-effective and personalized strategies for ongoing patient care. HIGHLIGHTS: In many patient-monitoring settings, the complications and costs of frequent tests are not justified for patients who are at low risk of disease progression. Predictions based on patient history may be used to individualize the timing of patient visits based on evolving risk.We propose Personalized Risk-Adaptive Surveillance (PRAISE), a novel method for personalizing the timing of surveillance testing, where prediction modeling projects the disease trajectory and a value-of-information (VOI)-based pragmatic decision-theoretic framework quantifies patient- and time-specific benefit-harm tradeoffs.A VOI-based approach to patient monitoring could be applied to several diseases to develop more personalized and cost-effective strategies for ongoing patient care.

Entities:  

Keywords:  dynamic decision making; dynamic prediction; personalized medicine; value of information

Mesh:

Substances:

Year:  2021        PMID: 34747265      PMCID: PMC9007840          DOI: 10.1177/0272989X211049213

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  26 in total

1.  Personalized screening intervals for biomarkers using joint models for longitudinal and survival data.

Authors:  Dimitris Rizopoulos; Jeremy M G Taylor; Joost Van Rosmalen; Ewout W Steyerberg; Johanna J M Takkenberg
Journal:  Biostatistics       Date:  2015-08-28       Impact factor: 5.899

2.  Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach.

Authors:  C L Faucett; D C Thomas
Journal:  Stat Med       Date:  1996-08-15       Impact factor: 2.373

3.  Chronic myelogenous leukemia, version 1.2015.

Authors:  Susan O'Brien; Jerald P Radich; Camille N Abboud; Mojtaba Akhtari; Jessica K Altman; Ellin Berman; Peter Curtin; Daniel J DeAngelo; Michael Deininger; Steven Devine; Amir T Fathi; Jason Gotlib; Madan Jagasia; Patricia Kropf; Joseph O Moore; Arnel Pallera; Vishnu Vb Reddy; Neil P Shah; B Douglas Smith; David S Snyder; Meir Wetzler; Kristina Gregory; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

4.  Optimal Policies for Reducing Unnecessary Follow-up Mammography Exams in Breast Cancer Diagnosis.

Authors:  Oguzhan Alagoz; Jagpreet Chhatwal; Elizabeth S Burnside
Journal:  Decis Anal       Date:  2013-09

5.  Survival effect of lung transplantation among patients with cystic fibrosis.

Authors:  T G Liou; F R Adler; B C Cahill; S C FitzSimmons; D Huang; J R Hibbs; B C Marshall
Journal:  JAMA       Date:  2001-12-05       Impact factor: 56.272

6.  Patient factors associated with lung transplant referral and waitlist for patients with cystic fibrosis and pulmonary fibrosis.

Authors:  Yuan Liu; Monica Vela; Tanya Rudakevych; Christopher Wigfield; Edward Garrity; Milda R Saunders
Journal:  J Heart Lung Transplant       Date:  2016-08-21       Impact factor: 10.247

7.  American Cancer Society prostate cancer survivorship care guidelines.

Authors:  Ted A Skolarus; Andrew M D Wolf; Nicole L Erb; Durado D Brooks; Brian M Rivers; Willie Underwood; Andrew L Salner; Michael J Zelefsky; Jeanny B Aragon-Ching; Susan F Slovin; Daniela A Wittmann; Michael A Hoyt; Victoria J Sinibaldi; Gerald Chodak; Mandi L Pratt-Chapman; Rebecca L Cowens-Alvarado
Journal:  CA Cancer J Clin       Date:  2014-06-10       Impact factor: 508.702

8.  The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.

Authors:  Emily A Knapp; Aliza K Fink; Christopher H Goss; Ase Sewall; Josh Ostrenga; Christopher Dowd; Alexander Elbert; Kristofer M Petren; Bruce C Marshall
Journal:  Ann Am Thorac Soc       Date:  2016-07

9.  A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management.

Authors:  Natalia R Kunst; Fernando Alarid-Escudero; A David Paltiel; Shi-Yi Wang
Journal:  Value Health       Date:  2019-08-07       Impact factor: 5.101

10.  Cystic fibrosis physicians' perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States.

Authors:  Kathleen J Ramos; Ranjani Somayaji; Erika D Lease; Christopher H Goss; Moira L Aitken
Journal:  BMC Pulm Med       Date:  2017-01-19       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.